Treatment News : Encouraging Data From Second Tesamorelin Study for Lipo - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » August 2008

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 13, 2008

Encouraging Data From Second Tesamorelin Study for Lipo

by Tim Horn

Treatment with a tesamorelin, a synthetic compound being developed by Theratechnologies in Montreal that sparks the production of natural human growth hormone, resulted in a significant loss of visceral adipose tissue (VAT)—deep belly fat—compared with a placebo in people with lipodystrophy, according to new results reported August 5 at the XVII International AIDS Conference in Mexico City. These data come from the first half of a second confirmatory Phase III clinical trial of the drug and are similar to results seen in the first trial reported in December 2007.

The reported tesamorelin study is a 52-week trial. During the first 26 weeks, 270 patients—about two-thirds of the enrolled study volunteers—received tesamorelin and one-third (126 patients) received a placebo. During the second 26 weeks of the study, those who originally received the placebo will switch to tesamorelin, while those who originally received tesamorelin will either stay on the drug or be switched to placebo.

After the first six months in the study, researcher Steven Grinspoon, MD, of Harvard Medical School in Boston reported that those who received tesamorelin had a 10.9 percent decrease in VAT compared with a 0.6 percent decrease in those who received a placebo. The primary goal of the study was an 8 percent decrease in VAT, indicating that the results are clinically meaningful.

The volume of subcutaneous adipose tissue—fat directly below the skin—increased by an average of 1.1 percent in the tesamorelin group and 0.9 percent in the placebo group. 

Patients in the tesamorelin group also had greater improvements in insulin function than those in the placebo group. Most important, there were no significant differences in glucose levels between the two groups after 26 weeks—a noted problem in clinical trials of Serono’s Serostim (recombinant human growth hormone) for lipodystrophy and a potential risk for diabetes.

The frequency of side effects was similar between both groups, with injection-site redness, rash, bruises; joint and extremity pain; and diarrhea being the most common side effects reported.

Search: tesamorelin, lipodystrophy, HARS, VAT, fat, growth hormone, Theratechnologies


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.